Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years, Pediatr Blood Cancer, vol.60, pp.213-232, 2010. ,
Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: Results of an international phase 2 study, Blood, vol.126, pp.1415-1423, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01231424
Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification, Blood, vol.111, pp.2556-2562, 2008. ,
Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society-Late Effects Study Group, Pediatr Blood Cancer, vol.42, pp.438-444, 2004. ,
, Cell Histiocytosis Study Group: A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group, Arch Dis Child, vol.75, pp.17-24, 1996.
, Recurrent BRAF mutations in Langerhans cell histiocytosis, vol.211, pp.1919-1923, 2010.
B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease, PLoS One, vol.7, issue.e33891, 2012. ,
High prevalence of BRAF V600E mutations in ErdheimChester disease but not in other non-Langerhans cell histiocytoses, Blood, vol.120, pp.2700-2703, 2012. ,
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation, Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, vol.121, pp.836-838, 2000. ,
, Pediatr Blood Cancer, vol.51, pp.71-75, 2008.
, Langerhans cell histiocytosis: Therapeutic strategy
URL : https://hal.archives-ouvertes.fr/hal-01331987
Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis, Expert Opin Pharmacother, vol.43, pp.1309-1322, 2004. ,
,
, Ann Surg Oncol, vol.19, pp.4314-4321, 2012.
Congenital solitary histiocytoma: A variant of Hashimoto-Pritzker histiocytosis. A retrospective study of 8 cases, Dermatology, vol.11, pp.118-124, 2008. ,
Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF (V600E)-mutated Erdheim-Chester disease, HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis, vol.48, pp.64-71, 2015. ,
, The BRAF-V600E mu, vol.124, pp.2610-2611, 2014.
, French Reference Center for Langerhans Cell Histiocytosis
, Trousseau Hospital
,
, Robert Debré Hospital
,
, Institut Curie Medical Center
,
, Pitié-Salpêtrière Hospital
, Tenon Hospital
,
, Ambroise Paré Hospital
, Nantes
,
,
Institut d'Hémato-Oncologie Pediatrique, Lyon; Valérie Rigau, Gui de Chauliac Hospital ,
, Claire Galambrun
,
,
,
Centre Hospitalo-Universitaire d ,
,
,
,
, Memorial Sloan Kettering Cancer Center